Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CHRND | Q07001 | 3/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.53 |
| ▸ | CHRNG | P07510 | 1/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378369 | 0.91 | PTPN1 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL25378366 | 0.91 | PTPN1 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL14598333 | 0.89 | CTSS (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL26222671 | 0.89 | PSMB1 (0.55) | PTPN1PSMB1PSMB5PSMB2CTSS | |
| SCHEMBL18072620 | 0.86 | ACE (0.56) | CTSSCTSLCTSBCTSK | |
| SCHEMBL25380517 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL25380527 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL6369971 | 0.86 | ACE (0.67) | CTSSCTSLCTSBCTSK | |
| SCHEMBL7430939 | 0.86 | REN (0.58) | PSMB1PSMB5PSMB2CTSSCTSL | |
| SCHEMBL16909161 | 0.84 | CTSS (0.67) | PTPN1CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057827-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| WO-2023161875-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057827-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | CYTH2, CYTH3, CD47 | CHRNB2 1270/4885CHRNB4 2152/4885CHRNA3 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.